Breaking the big Five Barriers of Brain Metastasis, (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous nonsmall-cell lung cancer (NSCLC) metastatic to the brain
